Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
Century Therapeutics announced an oral presentation of their CNTY-813 iPSC-derived islet cell replacement therapy at the American Diabetes Association's 86th Scientific Sessions. The company highlights progress in developing a scalable, off-the-shelf cell therapy platform engineered to reduce reliance on immunosuppressive drugs for type 1 diabetes …